| Reference | 1: Swain RP, Subudhi BB. Effect of semicrystalline polymers on self-emulsifying
solid dispersions of nateglinide: in vitro and in vivo evaluation. Drug Dev Ind
Pharm. 2017 Sep 11:1-10. doi: 10.1080/03639045.2017.1371739. [Epub ahead of
print] PubMed PMID: 28845687.
<br>
2: Li H, Kim HW, Shin SE, Seo MS, An JR, Jung WK, Ha KS, Han ET, Hong SH, Bang H,
Choi IW, Na SH, Park WS. The vasorelaxant effect of antidiabetic drug nateglinide
via activation of voltage-dependent K(+) channels in aortic smooth muscle.
Cardiovasc Ther. 2017 Aug 20. doi: 10.1111/1755-5922.12299. [Epub ahead of print]
PubMed PMID: 28834298.
<br>
3: Sultan AA, El-Gizawy SA, Osman MA, El Maghraby GM. Niosomes for oral delivery
of nateglinide: in situ-in vivo correlation. J Liposome Res. 2017 Jul 2:1-9. doi:
10.1080/08982104.2017.1343835. [Epub ahead of print] PubMed PMID: 28618876.
<br>
4: Wairkar S, Gaud R, Jadhav N. Enhanced dissolution and bioavailability of
Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro
and in-vivo evaluation. J Pharm Pharmacol. 2017 Sep;69(9):1099-1109. doi:
10.1111/jphp.12756. Epub 2017 Jun 7. PubMed PMID: 28590055.
<br>
5: Sharma A, de Souza Brito F, Sun JL, Thomas L, Haffner S, Holman RR, Lopes RD.
Noncardiovascular deaths are more common than cardiovascular deaths in patients
with cardiovascular disease or cardiovascular risk factors and impaired glucose
tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose
Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J. 2017 Apr;186:73-82.
doi: 10.1016/j.ahj.2016.12.011. Epub 2016 Dec 29. PubMed PMID: 28454835.
<br>
6: Tostes GC, Cunha MR, Fukui RT, Correia MR, Rocha DM, Dos Santos RF, da Silva
ME. Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells,
GLP-1 secretion and inflammatory markers in patients with type 2 diabetes:
randomized crossover clinical study. Diabetol Metab Syndr. 2016 Jan 4;8:1. doi:
10.1186/s13098-015-0120-6. eCollection 2016. PubMed PMID: 26734075; PubMed
Central PMCID: PMC4700605.
<br>
7: Zheng L, Wang J, Zhang J, Song Z, Dong Y, Wang Y, Tong Z, Deng C, Yin Y, Meng
M, Xi R. Preparation of polyclonal antibodies for nateglinide (NTG) and
development of a sensitive chemiluminescent immunoassay to detect NTG in tablets
and serum. Talanta. 2016;146:483-9. doi: 10.1016/j.talanta.2015.09.008. Epub 2015
Sep 9. PubMed PMID: 26695294.
<br>
8: Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development and in vitro/in
vivo evaluation of controlled release provesicles of a nateglinide-maltodextrin
complex. Acta Pharm Sin B. 2014 Oct;4(5):408-16. doi: 10.1016/j.apsb.2014.08.001.
Epub 2014 Sep 4. PubMed PMID: 26579411; PubMed Central PMCID: PMC4629096.
<br>
9: Tanimoto M, Kanazawa A, Hirose T, Yoshihara T, Kobayashi-Kimura S, Nakanishi
R, Tosaka Y, Sasaki-Omote R, Kudo-Fujimaki K, Komiya K, Ikeda F, Someya Y, Mita
T, Fujitani Y, Watada H. Comparison of sitagliptin with nateglinide on
postprandial glucose and related hormones in drug-naïve Japanese patients with
type 2 diabetes mellitus: A pilot study. J Diabetes Investig. 2015
Sep;6(5):560-6. doi: 10.1111/jdi.12338. Epub 2015 Mar 15. PubMed PMID: 26417414;
PubMed Central PMCID: PMC4578496.
<br>
10: Wairkar S, Gaud R. Co-Amorphous Combination of Nateglinide-Metformin
Hydrochloride for Dissolution Enhancement. AAPS PharmSciTech. 2016
Jun;17(3):673-81. doi: 10.1208/s12249-015-0371-4. Epub 2015 Aug 28. PubMed PMID:
26314243.
|
